Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort - Scorecard - MDSpire

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

  • By

  • Augustin Boudry

  • Laurène Fenwarth

  • Raphaël Itzykson

  • Thorsten Braun

  • Lionel Adès

  • Élise Fournier

  • Céline Berthon

  • Delphine Lebon

  • Stéphane De Botton

  • Régis Peffault de Latour

  • Cécile Pautas

  • Hervé Dombret

  • Emmanuel Raffoux

  • Claude Gardin

  • Karine Celli-Lebras

  • Claude Preudhomme

  • Nicolas Duployez

  • May 28, 2026

  • 0 min

Share

Clinical Scorecard: Next-Generation Sequencing with Ultra-High Sensitivity for MRD Assessment Predicts Outcomes in Older Patients with Acute Myeloid Leukemia: Findings from the ALFA-1200 Study

At a Glance

CategoryDetail
Condition
Key MechanismsMeasurable residual disease (MRD) assessment using ultra-high-sensitivity next-generation sequencing (UHS-NGS) should be abbreviated consistently.
Target Population
Care Setting

Key Highlights

  • remove

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients aged 60 years or older with AML treated with intensive chemotherapy.

          Standard intensive induction chemotherapy followed by intermediate-dose cytarabine for those achieving complete remission.

          Clinical Best Practices

          • remove

          Related Resources & Content

          Original Source(s)

          Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

          • by Augustin Boudry, Laurène Fenwarth, Raphaël Itzykson, Thorsten Braun, Lionel Adès, Élise Fournier, Céline Berthon, Delphine Lebon, Stéphane De Botton, Régis Peffault de Latour, Cécile Pautas, Hervé Dombret, Emmanuel Raffoux, Claude Gardin, Karine Celli-Lebras, Claude Preudhomme, Nicolas Duployez

          • May 28, 2026

          Related Content

          Synthetic short RNA in cancer

          Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

          Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report